Pacira enrolls first patient in Phase 2 ASCEND Part B trial of knee osteoarthritis gene therapy PCRX-201
PCRX•First patient enrolled in ASCEND Part B
Pacira Biosciences shifted PCRX-201, an investigational gene therapy for knee osteoarthritis, to a U.S.-based commercial-scale manufacturing process.
Drug supply from the new process enabled first patient enrollment in Part B of the Phase 2 ASCEND study.
Part A enrollment ended in June; topline results are expected by end of 2026 and have not yet been presented.
Management framed the manufacturing transition as de-risking later-stage development by generating Phase 2 data with the intended commercial process.
